T cell immune responses against melanoma and melanocytes in cancer and autoimmunity

Pigment Cell Research

Volumn 13, Issue SUPPL. 8, 2000, Pages 163-169

  Kawakami, Yutaka ^a,b   Suzuki, Yuriko ^a   Shofuda, Tomoko ^a   Kiniwa, Yukiko ^a   Inozume, Takashi ^a   Dan, Katsuaki ^a   Sakurai, Toshiharu ^a   Fujita, Tomonobu ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Mail Code 160 8582 ^*  (Japan)

Author keywords

Autoantigens; Cryptic self epitopes; Tumor antigens; Vitiligo; VKH

Indexed keywords

ARTICLE; AUTOIMMUNITY; HUMAN; IMMUNOLOGY; MELANOCYTE; MELANOMA; MENINGOENCEPHALITIS; NEOPLASM; SYMPATHETIC OPHTHALMIA; T LYMPHOCYTE; VITILIGO;

AUTOIMMUNITY; HUMANS; MELANOCYTES; MELANOMA; NEOPLASMS; OPHTHALMIA, SYMPATHETIC; T-LYMPHOCYTES; UVEOMENINGOENCEPHALITIC SYNDROME; VITILIGO;

EID: 0034565450     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0749.13.s8.29.x     Document Type: Article

References (50)

1. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. J Am Med Assoc 1994;271:907-913
2. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1995;86:1159-1166
3. Kawakami Y. Immunotherapy using T cell defined tumor antigens for melanoma. Microbiol Immunol 1998;42:803-813
4. Kawakami Y, Eliyahu S, Delgaldo CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 1994;91:3515-3519
5. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JB, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 1994;180:347-352
6. Kawakami Y, Rosenberg S. Human tumor antigens recognized by T-cells. Immunol Res 1997;16:313-339
7. Van Pel A, van der Brugen P, Coulie PG, Brichard VG, Lethe B, van der Eynde B, Uyttenhove C, Renauld J-C, Boon B. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 1995;145:229-250
8. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995;55:3478-3482
9. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated b-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-1192
10. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer Zum Buschenfelde K-H, Beach D. A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995;269:1281-1284
11. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Prfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-1792
12. Saraste M, Sibbald PR, Wittinghofer A. The P-loop - a common motif in ATP- and GTP-binding proteins. Trends Biochem Sci 1990;15:430-434
13. Pieper R, Christian R, Gonzales M, Nishimura M, Gupta G, Settlage R, Shabanowitz J, Rosenberg S, Hunt D, Topalian S. Biochemical identification of a mutated human melanoma antigen recognized by CD4+ T cells. J Exp Med 1999;189:757-765
14. Wang RF, Wang X, Rosenberg SA. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med 1999;189:1659-1667
15. Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr-transformed B cells. Int J Cancer 1994;58:69-79
16. Kawakami Y, Dang N, Wang X, Tupesis J, Robbins P, Wunderlich J, Yannelli J, Rosenberg S. Recognition of shared melanoma antigens in association with major HLA-A alleles by tumor infiltrating T lymphocytes from 123 patients with melanoma. J Immunother; in press.
17. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045
18. Wang S, Bartido S, Yang G, Qin J, Moroi Y, Panageas KS, Lewis JJ, Houghton AN. A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol 1999;163:5820-5826
19. Altman JD, Moss PA, Goulder PJR, Barouch DH, McHeyzer-Williams MG, Bell JI, McMichael AJ, Davis MM. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996;274:94-96
20. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Jhonson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor associated antigens in melanoma patients. Nat Med 1999;5:677-685
21. Pittet M, Valmori D, Dunbar P, Speiser D, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Ceroltini J, Romero P. High frequencies of native melan-A/MART-1-specific CD8+ T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999;190:705-715
22. Rivoltini L, Kawakami Y, Sakaguchi K, Southwood S, Sette A, Robbins PF, Marincola FM, Salgaller ML, Yannelli JR, Appella E, Rosenberg SA. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-2265
23. Marincola FM, Rivoltini L, Salgaller ML, Player M, Rosenberg SA. Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: Evidence for in vivo priming by tumor cells. J Immunother 1996;19:266-277
24. Loftus DJ, Castelli C, Clay TM, Squarcina P, Marincola FM, Nichimura MI, Parmiani G, Appella E, Rivoltini L. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-127-35. J Exp Med 1996;184:647-657
25. Kawakami Y, Rosenberg S. T-cell recognition of self peptides as tumor rejection antigens. Immunol Res 1995;15:179-190
26. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X-Q, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp100 associated with in vivo tumor regression. J Immunol 1995;154:3961-3968
27. Skipper JC, Gulden PH, Hendrickson RC, Harthun N, Caldwell JA, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CLJr. Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100. Int J Cancer 1999;82:669-677
28. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, Chen JL, Lienard D, Cerottini JC, Cerundolo V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998;188:1641-1650
29. Halaban R, Cheng E, Zhang Y, Moellmann G, Hanlon D, Michalak M, Setaluri V, Hebert DN. Aberrant retention of tyrosinase in the endoplasmic reticulum mediates accelerated degradation of the enzyme and contributes to the dedifferentiated phenotype of amelanotic melanoma cells. Proc Natl Acad Sci USA 1997;94:6210-6215
30. Nordlund JJ, Kirkwood JM, Forget BM, Milton G, Albert DM, Lerner AB. Vitiligo in patients with metastatic melanoma: A good prognostic sign. J Am Acad Dermatol 1983;9:689-695
31. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992;10:1338-1343
32. Rosenberg SA, White DE. Vitiligo in patients with melanoma: Normal tissue antigens can be target for cancer immunotherapy. J Immunother 1996;19:81-84
33. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA. Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994;91:6458-6462
34. Rosenberg S, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S, Restifo N, Dudley M, Schwarz S, Spiess P, Wunderlich J, Parkhurst M, Kawakami Y, Seipp C, Einhorn J, White D. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998;4:321-327
35. Parkhurst MR, Salgaller M, Southwood S, Robbins P, Sette A, Rosenberg SA, Kawakami Y. Improved induction of melanoma reactive CTL with peptides from the melanoma anticen gp100 modified at HLA-A020I binding residues. J Immunol 1996;157:2539-2548
36. Rosenberg S, Yang J, Schwartzentruber D, Hwu P, Marincola F, Topalian S, Restifo N, Sznol M, Schwarz S, Spiess P, Wunderlich J, Seipp C, Einhorn J, Rogers-Freezer L, White D. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol 1999;163:1690-1695
37. Moorthy RS, Inomata H, Rao NA. Vogt-Koyanagi-Harada syndrome. Surv Ophthalmol 1995;39:265-292
38. Shindo Y, Ohno S, Yamamoto T, Nakamura S, Inoko H. Complete association of the HLA-DRB1*04 and -DQB1*04 alleles with Vogt-Koyanaei-Harada's disease. Hum Immunol 1994;39:169-176
39. Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanasi-Harada disease. Br J Ophthalmol 1996;80:1002-1008
40. Sugita S, Sagawa K, Mochizuki M, Shichijo S, Itoh K. Melanocyte lysis by cytotoxic T lymphocytes recognizing the MART-1 melanoma antigen in HLA-A2 patients with Vogt-Koyanagi-Harada disease. Int Immunol 1996;8:799-803
41. Nakamura S, Nakazawa M, Yoshioka M, Nagano I, Nakamura H, Onodera J, Tamai M. Melanin-laden macrophages in cerebrospinal fluid in Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol 1996;114:1184-1188
42. Kobayashi H, Kokubo T, Takahashi M, Sato K, Miyokawa N, Kimura S, Kinouchi R, Katagiri M. Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 1998;47:398-403
43. Song YH, Connor E, Li Y, Zorovich B, Balducci P, Maclaren N. The role of tyrosinase in autoimmune vitiligo. Lancet 1994;344:1049-1052
44. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to human melanocyte-specific protein pme117 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay (RIA). Clin Exp Immunol 1998;114:333-338
45. Xie Z, Chen D, Jiao D, Bystryn JC. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol 1999;135:417-422
46. Ogg G, Dunbar P, Romero P, Chen J, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208
47. Wang RF, Wang X, Atwood AC, Topalian SL, Rosenberg SA. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 1999;284:1351-1354
48. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3:342-349
49. Old L, Chen Y. New paths in human cancer serology. J Exp Med 1998;187:1163-1167
50. Velculescu V, Zhang L, Vogelstein B, Kinzler K. Serial analysis gene expression. Science 1995;270:484-487